1. Home
  2. AMCI vs SPRO Comparison

AMCI vs SPRO Comparison

Compare AMCI & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AMCI

AMC Robotics Corporation Common Stock

N/A

Current Price

$6.30

Market Cap

157.4M

Sector

Finance

ML Signal

N/A

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.39

Market Cap

135.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMCI
SPRO
Founded
2021
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.4M
135.8M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
AMCI
SPRO
Price
$6.30
$2.39
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
1.4M
226.8K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.20
N/A
Revenue
$6,878,315.00
$40,549,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$30.46
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.51
52 Week High
$42.00
$3.22

Technical Indicators

Market Signals
Indicator
AMCI
SPRO
Relative Strength Index (RSI) 46.83 47.48
Support Level $6.00 $2.37
Resistance Level $7.07 $2.47
Average True Range (ATR) 0.71 0.09
MACD -0.14 -0.01
Stochastic Oscillator 10.00 20.29

Price Performance

Historical Comparison
AMCI
SPRO

About AMCI AMC Robotics Corporation Common Stock

AMC Robotics Corp is an artificial intelligence services company that develops robotic solutions designed to support operational efficiency across sectors such as logistics and manufacturing. The company develops robotics and automation technologies designed to improve logistics operations. Its robots use sensors and visual AI to support real-time decision-making, contributing to safer and more efficient warehouse operations. It builds autonomous robots for use in logistics and warehousing.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: